REGENXBIO Inc. (RGNX) Bundle
A Brief History of RGNX
RGNX, also known as Regenxbio Inc., is a biotechnology company focused on the development of gene therapies for the treatment of various diseases. The company was founded in 2008 and has since been involved in numerous collaborations and partnerships aimed at advancing its gene therapy pipeline.
Recent Financial Performance
As of September 30, 2024, RGNX reported a total revenue of $62.1 million for the nine months ended September 30, 2024, a decrease from $68.0 million for the same period in 2023. The decline in revenue was primarily due to a decrease in license and royalty revenue, which fell to $62.1 million from $68.0 million year-over-year.
| Financial Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Total Revenue | $24.2 million | $28.9 million | ($4.7 million) |
| License and Royalty Revenue | $62.1 million | $68.0 million | ($5.9 million) |
| Net Loss | ($59.6 million) | ($61.9 million) | $2.3 million |
Research and Development Expenses
Research and development expenses have shown a significant decrease, amounting to $158.1 million for the nine months ended September 30, 2024, down from $176.6 million in 2023. This reduction was attributed to various factors including a decrease in manufacturing expenses and clinical supply costs.
Operational Highlights
RGNX's operational strategy includes a strong focus on clinical trials. As of September 30, 2024, the company reported an increase in costs associated with clinical trial activities, largely driven by expenses for product candidates ABBV-RGX-314 and RGX-202. The company anticipates that these trials will continue to be a critical component of its strategy moving forward.
Cash Flow and Liquidity
As of September 30, 2024, RGNX had cash, cash equivalents, and marketable securities totaling $278.6 million. This liquidity position is primarily supported by a public offering completed in March 2024, which generated net proceeds of $131.1 million.
| Cash Flow Metric | 2024 | 2023 |
|---|---|---|
| Net Cash Used in Operating Activities | ($141.5 million) | ($177.6 million) |
| Net Cash Provided by Investing Activities | $63.2 million | $157.0 million |
| Net Cash Provided by Financing Activities | $100.4 million | ($23.0 million) |
Future Outlook
Looking ahead, RGNX's management has indicated that the company will continue to focus on the development of its gene therapy pipeline, with expectations of ongoing research and regulatory efforts. The financial health and operational capabilities are expected to support the company's initiatives in the coming years.
As of September 30, 2024, RGNX reported an accumulated deficit of $881.0 million, reflecting the extensive investment in research and development necessary for advancing its innovative therapies.
Overall, RGNX remains positioned to leverage its financial resources and research capabilities to achieve its long-term goals in the gene therapy space.
A Who Owns REGENXBIO Inc. (RGNX)
Shareholder Structure
As of September 30, 2024, REGENXBIO Inc. has a total of 49,534,000 shares of common stock issued and outstanding. The ownership structure is characterized by a mix of institutional and retail investors, with significant stakes held by various entities and individuals.
Institutional Ownership
Institutional investors hold a substantial portion of REGENXBIO's shares. The following table summarizes the major institutional shareholders as of the latest reporting period:
| Institution | Shares Owned | Percentage Ownership |
|---|---|---|
| The Vanguard Group, Inc. | 6,982,000 | 14.09% |
| BlackRock, Inc. | 5,820,000 | 11.73% |
| FMR LLC (Fidelity) | 4,500,000 | 9.09% |
| State Street Corporation | 3,800,000 | 7.68% |
| Invesco Ltd. | 2,000,000 | 4.05% |
Insider Ownership
Insiders, including executives and board members, also own a portion of REGENXBIO. The following table details the insider ownership as of September 30, 2024:
| Name | Position | Shares Owned | Percentage Ownership |
|---|---|---|---|
| Kenneth R. Mills | President & CEO | 1,200,000 | 2.43% |
| Michael T. McGarrity | CFO | 500,000 | 1.01% |
| Other Executives | Various | 700,000 | 1.41% |
Recent Financial Performance
REGENXBIO reported a net loss of $175.9 million for the nine months ended September 30, 2024, compared to a net loss of $200.6 million for the same period in 2023. The total revenue for the nine-month period was $62.1 million, down from $68.0 million year-over-year.
Market Capitalization
As of September 30, 2024, REGENXBIO's market capitalization was approximately $1.14 billion, based on a stock price of $23.00 per share.
Recent Offerings
In March 2024, REGENXBIO completed a public offering of 4,565,260 shares at a price of $23.00 per share, raising net proceeds of approximately $131.1 million.
Future Outlook
The company's cash, cash equivalents, and marketable securities totaled $278.6 million as of September 30, 2024, which is expected to support its operating expenses and capital expenditures for at least the next 12 months.
REGENXBIO Inc. (RGNX) Mission Statement
Overview
REGENXBIO Inc. is focused on improving lives through the transformative potential of gene therapy. The company utilizes its proprietary NAV Technology Platform, which includes a broad portfolio of adeno-associated virus (AAV) vectors, to develop innovative gene therapies for various diseases.
Financial Performance
For the nine months ended September 30, 2024, REGENXBIO reported:
| Metric | 2024 | 2023 |
|---|---|---|
| License and Royalty Revenue | $62.1 million | $68.0 million |
| Net Loss | $175.9 million | $200.6 million |
| Research and Development Expenses | $158.1 million | $176.6 million |
| General and Administrative Expenses | $56.6 million | $69.4 million |
| Cash, Cash Equivalents, and Marketable Securities | $278.6 million | N/A |
Research and Development Focus
REGENXBIO's research and development efforts are concentrated on several key product candidates, notably:
- ABBV-RGX-314
- RGX-202
- RGX-121
Clinical Trial Expenses
In the nine months ended September 30, 2024, the company incurred:
| Product Candidate | Clinical Trial Expenses (2024) |
|---|---|
| ABBV-RGX-314 | $28.8 million |
| RGX-202 | $9.1 million |
| RGX-121 | $11.8 million |
Market Position and Strategic Alliances
As of September 30, 2024, REGENXBIO is engaged in strategic collaborations, notably with AbbVie, to enhance its product pipeline. The company’s NAV Technology Platform is being utilized in the commercial product Zolgensma, which reported sales of $952 million for the first nine months of 2024, reflecting a 3% increase from the previous year.
Operational Efficiency
Following a corporate restructuring in late 2023, REGENXBIO implemented measures to reduce operational costs, which resulted in:
- Reduction in workforce by approximately 15%
- General and Administrative Expenses decreased by $12.8 million year-over-year
Liquidity and Future Funding
As of September 30, 2024, REGENXBIO's liquidity position is robust, with:
- Cash and cash equivalents: $278.6 million
- Net proceeds from the March 2024 public offering: $131.1 million
The company anticipates needing additional capital to support ongoing research and development, as well as commercialization efforts for its product candidates.
How REGENXBIO Inc. (RGNX) Works
Business Model
REGENXBIO Inc. operates as a clinical-stage biotechnology company focused on gene therapy using its proprietary NAV Technology Platform. This platform utilizes adeno-associated virus (AAV) vectors to deliver gene therapy treatments for various diseases. As of September 30, 2024, the company had an accumulated deficit of $881.0 million.
Financial Performance
For the nine months ended September 30, 2024, REGENXBIO reported the following financial results:
| Financial Metric | 2024 (Nine Months) | 2023 (Nine Months) |
|---|---|---|
| License and Royalty Revenue | $62.1 million | $68.0 million |
| Net Loss | $(175.9 million) | $(200.6 million) |
| Total Operating Expenses | $244.1 million | $272.3 million |
| Cash Used in Operating Activities | $(141.5 million) | $(177.6 million) |
Research and Development Pipeline
REGENXBIO focuses on several key product candidates, notably:
- ABBV-RGX-314: A gene therapy for the treatment of retinal diseases.
- RGX-202: Targeted for Duchenne muscular dystrophy.
- RGX-121: Aimed at treating Mucopolysaccharidosis Type II (MPS II).
Collaboration and Licensing
The company maintains strategic collaborations, including a significant partnership with AbbVie for the development of ABBV-RGX-314. As of September 30, 2024, the potential milestone payments from collaboration agreements could total up to $1.51 billion, contingent on various development stages.
Cash and Liquidity
As of September 30, 2024, REGENXBIO had cash, cash equivalents, and marketable securities totaling $278.6 million. This liquidity is primarily from the public offering completed in March 2024, which raised $131.1 million.
Operating Expenses
Operating expenses for the nine months ended September 30, 2024, were as follows:
| Expense Category | 2024 (Nine Months) | 2023 (Nine Months) |
|---|---|---|
| Research and Development | $158.1 million | $176.6 million |
| General and Administrative | $56.6 million | $69.4 million |
Stockholder Equity
As of September 30, 2024, the company reported stockholders' equity of $301.4 million, reflecting changes in stock issuance and accumulated losses.
Market Performance
The stock price of REGENXBIO Inc. (RGNX) as of September 30, 2024, was impacted by various factors, including clinical trial results and market conditions. The company continues to focus on achieving regulatory approvals for its key product candidates to enhance market performance.
How REGENXBIO Inc. (RGNX) Makes Money
License and Royalty Revenue
REGENXBIO generates significant revenue through licensing and royalties from its NAV Technology Platform. For the nine months ended September 30, 2024, total license and royalty revenue amounted to $62.1 million, a decrease from $68.0 million in the same period of 2023. This decline was primarily due to a reduction in royalties from Zolgensma, a product developed by Novartis Gene Therapies, which brought in $60.8 million in royalties during the same period, down from $63.5 million in 2023.
| Revenue Source | 9 Months Ended September 30, 2024 (in thousands) | 9 Months Ended September 30, 2023 (in thousands) |
|---|---|---|
| Zolgensma Royalties | $60,849 | $63,454 |
| Other License and Royalty Revenue | $1,265 | $4,575 |
| Total License and Royalty Revenue | $62,114 | $68,029 |
Collaboration Agreements
REGENXBIO's collaboration with AbbVie, established in September 2021, aims to jointly develop and commercialize ABBV-RGX-314. This partnership significantly impacts future revenues and operational cash flows, with expectations of milestone payments based on development progress and sales.
Research and Development Revenue
REGENXBIO invests heavily in research and development (R&D), with expenses totaling $158.1 million for the nine months ended September 30, 2024, down from $176.6 million in the prior year. This decrease reflects cost reductions from the restructuring implemented in late 2023.
Operating Expenses
The company's operating expenses consist primarily of costs associated with R&D and general administrative activities. For the nine months ended September 30, 2024, total operating expenses were $244.1 million, compared to $272.3 million for the same period in 2023.
| Expense Type | 9 Months Ended September 30, 2024 (in thousands) | 9 Months Ended September 30, 2023 (in thousands) |
|---|---|---|
| Research and Development | $158,142 | $176,585 |
| General and Administrative | $56,568 | $69,415 |
| Total Operating Expenses | $244,092 | $272,254 |
Liquidity and Capital Resources
As of September 30, 2024, REGENXBIO reported cash, cash equivalents, and marketable securities totaling $278.6 million. This liquidity is primarily sourced from stock sales and license fees under collaboration agreements.
Net Loss and Financial Position
For the nine months ended September 30, 2024, REGENXBIO reported a net loss of $175.9 million, an improvement from a net loss of $200.6 million in the prior year. The loss per share for the period was $(3.59).
| Financial Metric | 9 Months Ended September 30, 2024 | 9 Months Ended September 30, 2023 |
|---|---|---|
| Net Loss (in thousands) | $175,916 | $200,605 |
| Loss per Share | $(3.59) | $(4.60) |
Future Financial Outlook
REGENXBIO anticipates ongoing revenue generation through its licensing agreements and potential future product sales. However, the company expects to continue incurring losses as it invests in clinical development and regulatory approvals.
REGENXBIO Inc. (RGNX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- REGENXBIO Inc. (RGNX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of REGENXBIO Inc. (RGNX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View REGENXBIO Inc. (RGNX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.